Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
复制标题
精神分裂症继发性抑郁症的治疗。
DOI：
--
复制
发表时间：
1979
影响因子：
--
通讯作者：
B. Astrachan
中科院分区：
文献类型：
--
作者：
B. Prusoff;D. Williams;M. Weissman;B. Astrachan
抗抑郁药和抗精神病药的联合使用已被广泛推荐，并在临床上广泛用于抑郁的精神分裂症患者。然而，联合用药对这些患者的价值还没有得到明确的证明。本文报告了一项双盲、随机、安慰剂对照临床试验的结果，旨在评价奋乃静联合阿米替林与单用奋乃静治疗35例出现抑郁症状的慢性精神分裂症患者的疗效。结果表明，在治疗4个月后，在奋乃静的基础上加用阿米替林比单用奋乃静更有效地减轻抑郁症状，但在减少思维障碍方面效果较差。这项研究的结论是，在通常的抗抑郁剂的基础上加用抗抑郁剂治疗精神分裂症继发性抑郁的价值应该得到审查。
The combination of antidepressants and neuroleptics has been widely recommended and commonly used clinically for the schizophrenic patient who becomes depressed. However, the value of the combination for these patients has not been clearly demonstrated. This report presents results of a double-blind, randomized, placebo-controlled clinical trial designed to evaluate the combination of perphenazine and amitriptyline hydrochloride with that of perphenazine alone in the treatment of 35 ambulatory chronic schizophrenic patients in whom depressive symptoms developed. Results showed that the addition of amitriptyline to perphenazine, when compared with perphenazine alone, was more effective in reducing symptoms of depression after four months of treatment, but less effective in reducing thought disorder. The study concludes that the value of adding an antidepressant to the usual neuroleptic in the treatment of secondary depression in schizophrenia should be reviewed.